Objective: Immediate type I and type III endoleaks after endovascular aneurysm repair (EVAR) could be persistent or temporary. Reintervention is necessary for persistent ones. Color-coded quantitative digital subtraction angiography (CQDSA) could provide a quantitative evaluation of the endoleak hemodynamics. We aimed to use CQDSA to quantify immediate type I and type III endoleaks after EVAR and to find a practical way to predict their outcomes.
Endovascular aneurysm repair (EVAR) has become a widely accepted and preferred alternative to open surgery for the treatment of anatomically suitable abdominal aortic aneurysm (AAA) because of its significantly lower 30-day morbidity and mortality. 1 However, endoleak remains one of the major complications and main reasons for reintervention after EVAR. 2, 3 It carries the risk of aneurysm enlargement and rupture, especially for type I and type III endoleaks. 4, 5 According to the European Collaborators on Stent/graft Techniques for aortic Aneurysm Repair (EUROSTAR) study, immediate endoleaks were identified on the completion angiogram of 17.4% of patients. 6 Theoretically, immediate type I or type III endoleak needs intervention at once. However, some slight endoleaks were observed to seal spontaneously. 7, 8 To date, there is no consensus on the evaluation and management of such immediate type I or type III endoleaks. Based on the anatomic and morphologic characteristics visualized by digital subtraction angiography (DSA), the assessment of such endoleaks and the necessity of immediate reintervention remain subjective. Color-coded quantitative digital subtraction angiography (CQDSA) provides an easy and quick way to postprocess the traditional DSA. CQDSA postprocessing converts the peak time of a time-intensity curve that corresponds to the maximal contrast medium intensity into a single polychromatic image. 9 This color-coded representation of the parameter time to peak (TTP) could directly quantify the hemodynamic characteristics after endovascular treatment. 10, 11 Patients are free from exposure to additional radiation and contrast medium. Currently, the clinical course of immediate type I and type III endoleaks after EVAR is unclear. Therefore, this study aimed to observe the outcomes of patients with such endoleaks and to evaluate whether CQDSA can predict the outcomes of type I and type III endoleaks after EVAR procedures.
METHODS
Selection of patients. This study was a prospective observational nested case-control study approved by the institutional ethical review committee.
From January 2012 to December 2014, a total of 485 consecutive patients with AAA underwent EVAR at our institution. The inclusion criteria included slight type I and type III endoleaks on the completion angiogram after EVAR, which operators decided to follow up; compliance to the designed follow-up plan; and age $18 years. The exclusion criteria were as follows: obvious type I and type III endoleaks treated during EVAR; type II endoleaks on the completion angiogram after EVAR; previous operations involving the abdominal aortic segment; AAA secondary to connective tissue diseases, such as Marfan syndrome or vasculitis; abdominal aortic dissection; and ruptured AAA. Thirty-five patients (31 men, four women) were finally recruited in this singlecenter study. Clinical decisions were not made or modified because of our study; informed consent was not required.
DSA protocol. DSA was performed using a standard angiographic system (Axiom Artis; Siemens Healthcare, Forchheim, Germany). To distinguish type III from type Ia endoleaks, we positioned a 5F pigtail catheter below the proximal fixation site in the main body of the stent graft. After completion of EVAR, the pigtail catheter was positioned at the level of T12 vertebral body for final angiography. A total volume of 20 mL of contrast agent (iohexol, 350 mg of iodine per milliliter [Omnipaque]; GE Healthcare, Cork, Ireland) was administered at 15 mL/s by a power injector with a 1-second delay. The acquisition parameters (C-arm fixed; anteroposterior and lateral views; six frames per second) were kept constant for each patient. Exposure time was controlled manually to ensure complete appearance of endoleaks.
CQDSA technique and data measurement. Original DSA data in Digital Imaging and Communications in Medicine format were collected and converted into polychromatic images on a workstation (syngo X Workplace; Siemens Healthcare) running syngo iFlow software (Siemens Healthcare). Time-intensity curves were obtained for each individual pixel or cluster of pixels. Two parameters were extracted automatically:
1. Maximal enhancement (I max ): I max was calculated as the difference between peak pixel intensity (I peak ) and pixel intensity in the mask frame (I mask ). 2. TTP referred to the delay time between the contrast medium injection and the arrival of I max .
The TTP and I max were color coded by using the HSV (hue, saturation, and value) color space and then converted to the red, green, blue color. The faster the contrast intensity increased to the peak, the warmer the color tone would be (red: minimum TTP; blue: maximum TTP). CQDSA images could visualize and quantify the time course of contrast agent arrival to the peak within the vasculature, superior to the simple opacification degree visualized on DSA. In addition, each selected region within the color-coded map could generate a time-intensity curve reflecting the contrast intensity changes over time.
Five raters blinded to either the study design or clinical outcomes were invited to draw a region of interest (ROI) with warmest color tone in the leakage lumen for each patient. Meanwhile, a reference area at the same latitude within the stent graft was also selected (Fig 1) . Timeintensity curves were generated for these two areas. The TTP was derived from the time-intensity curve (Fig 2) . The minimum TTP among the five selected ROIs and its reference area were used for analysis. To reduce the influence of the distance from contrast medium injection site to the ROI, heart rates and blood pressure, the relative value of TTP (DTTP), and the ratio of TTP between ROI and reference area (ROI TTP/Ref TTP) were also calculated.
Follow-up. After EVAR, all recruited patients were scheduled for follow-up at 3, 6, and 12 months and annually thereafter. Clinical status of each patient was assessed by experienced physicians who were blinded 
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Recommendation:
The authors suggest that colorcoded quantitative digital subtraction arteriography be used to predict endoleak-related adverse outcomes and the need for immediate reintervention.
to the study design. Computed tomography angiography (CTA) and color Doppler ultrasound (CDUS) were routinely performed. The primary outcomes were endoleak-related adverse events, including aneurysm sac enlargement (increase of maximum diameter $5 mm), persistent endoleak (endoleak existing for 6 months or more after EVAR), endoleak-related reintervention, and conversion to open repair due to endoleak. Secondary outcome was aneurysm rupture. We also collected some additional patient information that may potentially affect the development of endoleak, including the type of endoleak, anticoagulation or antiplatelet medication, and comorbid clinical conditions. Statistical analysis. All statistical analysis was conducted with Stata 12.0 (StataCorp, College Station, Tex). Intraclass correlation coefficient was generated to assess inter-rater variability. Baseline characteristics were compared between patients with and without endoleakrelated adverse events. Values were presented as proportions for categorical variables and mean 6 standard deviation for continuous variables. Student t-test was used to evaluate normally distributed continuous variables, Mann-Whitney U test for skewed variables. Because of small sample size (n < 40), the differences between categorical variables were compared by Fisher exact test. A receiver operating characteristic (ROC) curve was developed to test the ability of the parameter to predict endoleak-related adverse events and to identify the optimal cutoff value. The area under the curve (AUC) and 95% confidence interval (CI) were calculated to determine the predictive value. Logistic regression analysis was performed to identify the odds ratio (OR) value. All probability values were two tailed, and the 5% level was considered statistically significant.
RESULTS
Baseline characteristics. Of the 485 patients, a total of 49 patients with slight immediate type I and type III endoleaks at completion angiography were enrolled for evaluation. Six patients were excluded because of Marfan syndrome (n ¼ 1), inflammatory AAA (n ¼ 1), and O indicates area with minimum time to peak (TTP) in endoleak lumen; C indicates the reference area within the stent graft. abdominal aortic dissection (n ¼ 4); six were lost during follow-up, and two died of severe pneumonia and drug abuse, respectively, before the first follow-up. Finally, 35 patients (mean age, 72.8 years; 31 men, 4 women) were recruited in the study. Median follow-up time for all patients was 24.0 months (mean 6 standard deviation, 27.5 6 11.6 months). During the follow-up period, 12 (34.3%) patients experienced endoleak-related adverse events (aneurysm sac growth, 7; persistent endoleak, 11; reintervention due to endoleak, 8). None of the aneurysm ruptures had been observed until the end of this study. High level of inter-rater agreement was observed for TTP (intraclass correlation coefficient ¼ .923).
At baseline, the mean aortic neck length of 19 patients with type I endoleaks was 31.5 6 16.5 mm (range, 11-67 mm; one case of aortic neck length <15 mm), and the mean aortic neck angulation was 43. All patients were classified into two groups based on endoleak-related adverse events, and their baseline characteristics are shown in Table I . There were no significant differences in age, gender proportion, follow-up time, DTTP, ROI TTP/Ref TTP, hypertension, hyperlipidemia, diabetes mellitus, or anticoagulation and antiplatelet medication between the two groups. However, TTP of selected ROI was significantly lower in patients with endoleak-related adverse events. In addition, the risk of endoleak-related adverse events was significantly higher in patients with type I mixed with type III endoleak than in those with simple-type endoleak (P ¼ .003), but no significant difference was observed between type I and type III endoleaks (P ¼ 1.000). (Fig 3) . The optimal cutoff value was 5 seconds for TTP in predicting the endoleak-related adverse events (sensitivity, 91.67%; specificity, 69.57%; Fig 4) . Therefore, the predictive value of TTP in outcomes of endoleak is superior to that of DTTP and ROI TTP/Ref
TTP.
Logistic regression analysis. According to the optimal cutoff value of TTP, patients were classified into two groups (Table II) . Fisher exact test showed that TTP #5 seconds was associated with higher risk of endoleak-related adverse events (P ¼ .001). Logistic regression analysis demonstrated that TTP of ROI and the type of endoleak were two potential predictors of endoleak-related adverse events. The OR values of TTP #5 seconds and mixed-type endoleak were 21.0 (95% CI, 1.776-248.3; P ¼ .016) and 17.1 (95% CI, 1.074-272.7; P ¼ .044), respectively.
DISCUSSION
Endoleaks pose a high risk for aneurysm growth and rupture because of direct or indirect communication between the aneurysm sac and the systemic circulation. 5, 12 Currently, type II endoleaks are relatively common, occurring in 10% to 25% of patients who have undergone EVAR, but most of them have a benign clinical course and warrant only continuous imaging surveillance. [13] [14] [15] Because of the improvement of covered materials, type IV endoleaks are rare and transient. Conversely, type I and type III endoleaks are considered to have higher risk because of persistently increased sac pressure. 5 Various studies pointed out that type I and type III endoleaks require immediate intervention once they are detected, such as balloon angioplasty, cuff implantation, and bare stents. 12, 16 However, some researchers found that a number of slight type I endoleaks were self-limited or sealed spontaneously, which could be treated only when the aneurysm sac enlarged. 7, 8, 17 The best management of immediate type I and type III endoleaks detected during an EVAR procedure remains unclear. Moreover, the significance of these endoleaks on long-term outcomes is unknown. Therefore, we enrolled patients with slight immediate type I and type III endoleaks and kept them under surveillance. During our follow-up, 24 patients were observed to have spontaneously resolved endoleaks, and this was in accordance with previous reports. 7, 8, 18, 19 For these patients, surgical intervention as well as its costs are redundant. Thus, an objective evaluation method to predict the outcomes of such endoleaks during the EVAR procedure could help operators decide on whether to reintervene immediately. Conventional DSA is still the "gold standard" in diagnosis and classification of endoleaks. It allows dynamic and multiple-angle views of the aneurysm sac and stent graft. However, the results of DSA are limited to anatomic and morphologic characteristics. The evaluation of endoleak severity highly depends on the experience of the operators. With the development of imaging postprocess techniques, additional information can be extracted by the new method of CQDSA. Although it does not provide the absolute value of hemodynamics, the parameter TTP has been shown to be useful in reflecting the velocity of blood flow indirectly. 20 Moreover, colorful images make it easier to distinguish the slight changes in signal intensity than in monochromatic ones. In this study, we proved for the first time that CQDSA could help predict the outcomes of immediate endoleak after EVAR and prospectively identified the optimal cutoff value of TTP. The parameter TTP can be regarded as an index of hemodynamic characteristics in endoleak and can be immediately obtained from the CQDSA image while the patient is still on the operating table. This conversion takes only seconds with no radiographic exposure and no extra financial burden on each patient. To remove some technique glitches that may affect the TTP value, we strictly applied unified equipment parameters and standard injection protocols for each patient. An autoinjection ensured the same volume and injection rate of contrast medium. A 1-second injection delay allowed Continuous data are shown as the mean 6 standard deviation and categoric data are given as number (%). recording of the first image, namely, mask frame. Notably, previous studies used different frame rates, from two to six. [21] [22] [23] Increased frame rates do make the absolute time slightly different because of higher temporal resolution, but the difference is limited in 0.1 second. Thus, we chose the rate of six frames per second, and the overall results will not change a lot. In this study, we found that TTP was significantly lower in patients with endoleak-related adverse events than in those without endoleak-related adverse events. According to the ROC curve and logistic regression analysis, TTP #5 seconds was proved a potential predictor of endoleak-related adverse events. Because this study was an observational study, we had not changed our clinical practice according to TTP value. Meanwhile, considering that patients' heart rate, blood pressure, and other cardiovascular comorbidities, such as congestive heart failure and arteriomegaly, may affect the angiographic results, we tried to eliminate the effects of these patient factors using the relative value and ratio of TTP between the selected ROI and reference, but both of them failed to present significant predictive value. This was opposite to what we had expected. We supposed that not only the hemodynamic characteristics could be indicated by TTP but also some individual variations, such as the distance from heart to the endoleak lumen, heart rates, ejection fraction, blood viscosity, and morphology of the aneurysm sac. The parameter TTP actually integrated several factors affecting the outcomes of endoleak, whereas DTTP and ROI TTP/Ref TTP neglected these.
Apart from TTP, the type of endoleak is another potential predictor. Fisher exact test showed that the risks of endoleak-related adverse events were significantly higher in patients with type I mixed with type III endoleaks than in those with simple type I or type III endoleaks. Logistic regression analysis also confirmed that mixed-type endoleak was a reliable predictor of endoleak-related adverse events. We considered that mixed-type endoleaks were associated with more blood flow outside the stent graft and poor interaction between stent graft and aneurysm sac. Although no significant difference was observed between type I and type III endoleaks, it could be the result of small sample size. A prospective large-sample case-control study is warranted to verify it.
Although several imaging modalities have a place in endoleak surveillance, CTA remains the most widely used because of its high resolution, reproducibility, speed, and sensitivity to metallic stent. CTA allows the reconstruction of thin branch arteries and precise measurement of aneurysm size. Several studies indicated that CTA was more sensitive than DSA in the detection of endoleak. 24, 25 In our study, type II endoleaks were detected by CTA on follow-up in five patients (14.3%). It does not imply misdiagnosis during the EVAR procedure, but CTA is not as specific as DSA in endoleak classification because of the lack of dynamic visualization of blood flow. On completion angiography, type II endoleak was confirmed according to the delayed irrigation from inferior mesenteric or lumbar arteries. However, the contrast medium detected in the inferior mesenteric or lumbar arteries on CTA may be the outflow of type I and type III endoleaks. CDUS has a great advantage over computed tomography for enabling real-time observation of vascular lumen and flow direction. Moreover, Schmieder et al found that CDUS was better than computed tomography at determining the need for intervention. 26 Therefore, we combined CTA with CDUS in the follow-up of endoleaks. The evaluation and decision of reintervention were guided by the results of CTA and CDUS. Our study has several limitations. First, the sample size was small because of low incidence. Thus, the 95% CIs were wide for the OR value of TTP #5 seconds and mixed type of endoleak. Our study indicated that TTP #5 seconds might be a potential predictor of adverse endoleak-related events, but for further clinical application, a prospective study comparing the long-term outcomes of immediate reintervention and conservative therapy in patients with slight immediate type I or type III endoleaks and TTP #5 seconds is warranted. Second, considering that DSA is an invasive test, we were unable Fig 4. The sensitivity, specificity, and sum of sensitivity and specificity at different cutoffs of time to peak (TTP) in region of interest (ROI) to predict the outcomes of subjects. TTP #5 seconds is the cutoff with the maximum sum value.
to observe the changes of TTP during follow-up. Third, patients with delayed type I or type III endoleaks were not enrolled in our study. The outcomes of these patients were unclear. Finally, we did not compare the results of CQDSA with other hemodynamic tests, such as intraoperative measurement of aneurysm sac pressure or intrasac flow velocities.
CONCLUSIONS
CQDSA provides helpful support in predicting the outcomes of immediate endoleak after EVAR procedures with the additional parameter TTP. The optimal cutoff value for TTP was 5 seconds, and TTP #5 seconds was associated with higher risk of endoleak-related adverse events. In addition, the type of endoleak was another potential predictor. Therefore, accurate detection and classification of endoleak on DSA together with hemodynamic information offered by TTP could help clinicians in proper management. 
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